Search Result

Results for "

blood glucose

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SGLT (6) 11β-HSD (1) Adrenergic Receptor (1) Akt (1) Aldose Reductase (1) AMPK (6) Amylases (1) Antibiotic (1) Apoptosis (1) Bacterial (2) Biochemical Assay Reagents (4) Dipeptidyl Peptidase (3) Endogenous Metabolite (5) ERK (1) Estrogen Receptor/ERR (1) FBPase (1) Ferroptosis (2) Free Fatty Acid Receptor (1) GCGR (4) Glucocorticoid Receptor (1) Glucokinase (1) Glucosidase (14) GPR119 (1) Histone Acetyltransferase (1) Insulin Receptor (1) Isotope-Labeled Compounds (1) Mineralocorticoid Receptor (1) NF-κB (1) Nuclear Hormone Receptor 4A/NR4A (1) PEPCK (1) Phosphatase (3) PI3K (2) Potassium Channel (2) PPAR (10) Reactive Oxygen Species (1) STAT (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (2) Endocrinology (2) Infection (2) Inflammation/Immunology (2) Metabolic Disease (65) Neurological Disease (6)

By Targets:

SGLT (6)

11β-HSD (1)

Adrenergic Receptor (1)

Akt (1)

Aldose Reductase (1)

AMPK (6)

Amylases (1)

Antibiotic (1)

Apoptosis (1)

Bacterial (2)

Biochemical Assay Reagents (4)

Dipeptidyl Peptidase (3)

Endogenous Metabolite (5)

ERK (1)

Estrogen Receptor/ERR (1)

FBPase (1)

Ferroptosis (2)

Free Fatty Acid Receptor (1)

GCGR (4)

Glucocorticoid Receptor (1)

Glucokinase (1)

Glucosidase (14)

GPR119 (1)

Histone Acetyltransferase (1)

Insulin Receptor (1)

Isotope-Labeled Compounds (1)

Mineralocorticoid Receptor (1)

NF-κB (1)

Nuclear Hormone Receptor 4A/NR4A (1)

PEPCK (1)

Phosphatase (3)

PI3K (2)

Potassium Channel (2)

PPAR (10)

Reactive Oxygen Species (1)

STAT (1)

By Research Areas:

Cancer (9)

Cardiovascular Disease (2)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (2)

Metabolic Disease (65)

Neurological Disease (6)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: GLUT SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122613

YM543 free base	SGLT	Metabolic Disease
YM543 free base is a potent and orally active *sodium-glucose* cotransporter (SGLT) 2** inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes .

HY-12611

Sergliflozin etabonate GW-869682X	SGLT	Metabolic Disease
Sergliflozin etabonate (GW-869682X) is a potent and orally active *sodium glucose* cotransporter (SGLT2)** inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes .

HY-N12353

Stevisalioside A	Phosphatase	Metabolic Disease
Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC₅₀: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .

HY-121565

SaRI 59-801	Others	Metabolic Disease Endocrinology
SaRI 59-801 is an orally effective hypoglycemic compound. SaRI 59-801 decreases blood glucose in several species and to elevate plasma insulin in rats and mice .

HY-155961

Antidiabetic agent 2	Dipeptidyl Peptidase Phosphatase Amylases Glucosidase	Metabolic Disease
Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC₅₀s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels .

HY-N0936

Coixol 1 Publications Verification 6-Methoxy-2-benzoxazolinone; 6-MBOA	Others	Inflammation/Immunology
Coixol (6-Methoxy-2-benzoxazolinone; 6-MBOA) is a potent and orally active anti-inflammatory agent. Coixol decreases the iNOS protein expression. Coixol inhibits the production of TNF-α, IL-6, and IL-1β. Coixol improves glucose tolerance and plasma insulin. Coixol decreases the blood glucose level .

HY-148575

α-Glucosidase-IN-23	Glucosidase	Metabolic Disease
α-Glucosidase-IN-23 is an orally active α-Glucosidase inhibitor. α-Glucosidase-IN-23 decreases blood glucose by a-glucosidase inhibition with an IC₅₀ value of 4.48 μM. α-Glucosidase-IN-23 can be used for the research of diabetes .

HY-P5578

A8SGLP-1	GCGR	Metabolic Disease
A8SGLP-1 is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 reduces blood glucose in db/db mice without affecting its function .

HY-143226

DK1	Estrogen Receptor/ERR	Metabolic Disease
DK1 is a potent modulator of estrogen related receptor. DK1 has an ability in reducing blood glucose, and impacts the activity of ERRα receptor. DK1 has the potential for the research of diabetes .

HY-P5578A

A8SGLP-1 TFA	GCGR	Metabolic Disease
A8SGLP-1 TFA is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 TFA reduces blood glucose in db/db mice without affecting its function .

HY-150560

α-Glucosidase-IN-11	Glucosidase	Metabolic Disease
α-Glucosidase-IN-11 is a highly permeable competitive α-glucosidase inhibitor with the IC₅₀ value of 0.56 μM. α-Glucosidase-IN-11 binds to Trp residues in α-glucosidase and regulates protein folding. α-Glucosidase-IN-11 can be used to regulate blood glucose levels .

HY-103433

K579	Dipeptidyl Peptidase	Metabolic Disease
K579 is a potent and orally active dipeptidyl peptidase IV inhibitor. K579 inhibits the blood glucose elevation. K579 increases the plasma insulin and active forms of glucagon-like peptide-1 (GLP-1). K579 has the potential for the research of diabetic .

HY-14860

1-Deoxynojirimycin 3 Publications Verification Duvoglustat	Glucosidase PI3K	Metabolic Disease
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-14860A

1-Deoxynojirimycin hydrochloride 3 Publications Verification Duvoglustat hydrochloride	Glucosidase PI3K Bacterial Antibiotic	Infection Metabolic Disease
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-148189

Aldometanib 2 Publications Verification LXY-05-029	AMPK	Metabolic Disease
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis .

HY-151138

α-Glucosidase-IN-16	Glucosidase	Metabolic Disease
α-Glucosidase-IN-16 is a potent and orally active α-glucosidase inhibitor with an IC₅₀ value of 3.28 μM. α-Glucosidase-IN-16 can reduce the level of blood glucose in Streptozotocin-induced diabetic rats. Antidiabetic activity .

HY-15344

(R,R)-BD-AcAc 2 1 Publications Verification (R,R)-Ketone Ester	Others	Neurological Disease Metabolic Disease
(R,R)-BD-AcAc 2 ((R,R)-Ketone Ester), a ketone monoester, can be used as a source of oral nutritional ketones. (R,R)-BD-AcAc 2 can elevate plasma levels of β-hydroxybutyrate and acetoacetate, blood glucose, blood Na ⁺ levels and blood creatinine levels after oral administration in mice. (R,R)-BD-AcAc 2 can partly prevent muscle weakness in septic mice. (R,R)-BD-AcAc 2 has potential to improve exercise performance and endurance in animal body. (R,R)-BD-AcAc 2 can also be used to research Parkinson’s disease or diabetes .

HY-B0920

Tolazamide

U-17835
Others Endocrinology

Tolazamide is an oral blood glucose lowering drug used for people with Type 2 diabetes.

Tolazamide U-17835	Others	Endocrinology
Tolazamide is an oral blood glucose lowering drug used for people with Type 2 diabetes.

HY-107863

Fructooligosaccharides Oligolevulose	Biochemical Assay Reagents	Metabolic Disease
Fructooligosaccharides (Oligolevulose) is a beneficial sugar which can be produced by the microbial flora. Fructooligosaccharides had no significant effect on blood glucose, blood lipid and serum acetate in diabetic model .

HY-157370

Blood Enrichment Medium	Biochemical Assay Reagents	Others
Blood Enrichment Medium can be used for enrichment culture of pathogenic bacteria in blood. Blood Enrichment Medium ingredients include peptone, beef extract powder, NaCl, glucose, sodium citrate, para-aminobenzoic acid, magnesium sulfate, phenol red .

HY-N1503

Methyl deacetylasperulosidate 6α-Hydroxygeniposide; Deacetylasperulosidic acid methyl ester
Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .

HY-W010031

1-Methyluric acid	Endogenous Metabolite	Metabolic Disease
1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels.

HY-N2421

Sequoyitol 1 Publications Verification 5-O-Methyl-myo-inositol	Others	Metabolic Disease
Sequoyitol (5-O-Methyl-myo-inositol) is isolated from plants. Sequoyitol (5-O-Methyl-myo-inositol) decreases blood glucose, improves glucose intolerance, and is used to treat diabetes .

HY-109018A

Velagliflozin proline 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline is an oral *sodium-glucose* cotransporter 2 (SGLT2*) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose* reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-U00340

PPAR agonist 1	PPAR	Metabolic Disease
PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.

HY-109018B

Velagliflozin proline hydrate	SGLT	Metabolic Disease
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral *sodium-glucose* cotransporter 2 (SGLT2*) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose* reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-128923

SKF-34288 hydrochloride 1 Publications Verification 3-Mercaptopicolinic acid hydrochloride; 3-MPA hydrochloride	PEPCK	Metabolic Disease
SKF-34288 (3-Mercaptopicolinic acid) hydrochloride is an orally active phosphoenolpyruvate carboxykinase (PEPCK) inhibitor (K_i: 2-9 μM). SKF-34288 hydrochloride is a potent hypoglycemic agent by inhibiting glucose synthesis. SKF-34288 hydrochloride also inhibits Asn metabolism and increases amino acids and amides .

HY-161281

α-Glucosidase-IN-49	Glucosidase	Metabolic Disease
α-Glucosidase-IN-49 (compound C23) is a potent inhibitor of α-Glucosidase, with IC₅₀ of 0.52 μM. α-Glucosidase-IN-49 has oral bioactivity that can reduce blood glucose and improve glucose tolerance in mice .

HY-12614

AMG-1694	Glucokinase	Metabolic Disease
AMG-1694 is a potent glucokinase–glucokinase regulatory protein (GK-GKRP) disruptors and promotes the dissociation of the GK-GKRP complex with an IC₅₀ of 7 nM, indirectly increasing GK enzymatic activity. AMG-1694 potently reverses the inhibitory effect of GKRP on GK activity and promotes GK translocation. AMG-1694 normalizes blood glucose levels in several rodent models of diabetes and lowes blood glucose restricted to diabetic and not normoglycaemic animals .

HY-148529

Midaglizole (±)-DG5128 free base; DG5128 free base	Adrenergic Receptor	Metabolic Disease
Midaglizole ((±)-DG5128 free base, DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo .

HY-12219B

MSI-1701

Others Metabolic Disease

MSI-1701 is an analogue of MSI-1436 which can control weight gain and blood glucose level extracted from patent US 7410959 B1.

MSI-1701	Others	Metabolic Disease
MSI-1701 is an analogue of MSI-1436 which can control weight gain and blood glucose level extracted from patent US 7410959 B1.

HY-N3960

Glycyrin	PPAR Bacterial	Infection Metabolic Disease
Glycyrin is a PPAR-γ ligand of licorice. Glycyrin can decrease the blood glucose levels of genetically diabetic mice. Glycyrin also shows antibacterial activity .

HY-101116

GLP-1R Antagonist 1 1 Publications Verification	GCGR	Metabolic Disease
GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC₅₀ of 650 nM .

HY-120160

Darglitazone CP-86325	PPAR	Neurological Disease Metabolic Disease
Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

HY-14810

Atigliflozin AVE-2268	SGLT	Metabolic Disease
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC₅₀s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .

HY-N4195

Resveratroloside 1 Publications Verification Resveratrol glycoside; trans-Resveratrol 4'-O-β-D-glucopyranoside	Glucosidase	Cardiovascular Disease Metabolic Disease
Resveratroloside (Resveratrol glycoside) is a competitive inhibitior of α-glucosidase with an IC₅₀ of 22.9 μM. Resveratroloside has the ability to regulate PBG (postprandial blood glucose) levels. Resveratroloside exhibits cardioprotective effect .

HY-151145

α-Glucosidase-IN-21	Glucosidase	Metabolic Disease
α-Glucosidase-IN-21 (Compound 2B) is a potent, orally active α-glucosidase inhibitor with an IC₅₀ of 2.62 μM. α-Glucosidase-IN-21 shows anti-diabetic activity .

HY-151143

α-Glucosidase-IN-19	Glucosidase	Metabolic Disease
α-Glucosidase-IN-19 (Compound 6B) is a potent, orally active α-glucosidase inhibitor with an IC₅₀ of 3.63 μM. α-Glucosidase-IN-19 shows anti-diabetic activity .

HY-151144

α-Glucosidase-IN-20	Glucosidase	Metabolic Disease
α-Glucosidase-IN-20 (Compound 3B) is a potent, orally active α-glucosidase inhibitor with an IC₅₀ of 3.01 μM. α-Glucosidase-IN-20 shows anti-diabetic activity .

HY-P3608

[Des-His1,Glu9] Glucagon	GCGR	Metabolic Disease
[Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .

HY-131334

AMPK activator 4	AMPK	Metabolic Disease
AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .

HY-120160A

Darglitazone Sodium CP 86325 Sodium	PPAR	Neurological Disease Metabolic Disease
Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

HY-N11551

Salvifaricin	Others	Others Metabolic Disease
Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .

HY-N3015

Bruceine E	Others	Metabolic Disease
Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ)-induced diabetic rats at lower dose .

HY-156276

SP4e	PPAR	Metabolic Disease
SP4e is an activator of PPAR-γ, with the EC₅₀ of 739 nM in HK-2 cells. SP4e reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .

HY-156277

SP4f	PPAR	Metabolic Disease
SP4f is an activator ofPPAR-γ, with the EC₅₀ of 826 nM in HK-2 cells. SP4f reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .

HY-W145497

D-(+)-Sorbose	Insulin Receptor	Metabolic Disease
D-(+)-Sorbose, an active enantiomer of D-Sorbose, which inhibits disaccharidase activity and demonstrates suppressive action on postprandial blood levels of glucose and insulin in the rat. D-sorbose acts as a sweetener may contribute to the prevention of lifestyle-related diseases, such as type 2 diabetes mellitus .

HY-13956

Pioglitazone Maximum Cited Publications 25 Publications Verification U 72107	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-13956B

Pioglitazone potassium U 72107 potassium	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) potassium is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research .

HY-149409

α-Glucosidase-IN-31	Glucosidase	Metabolic Disease
α-Glucosidase-IN-31 (compound R1) is an orally active, potent α-Glucosidase inhibitor with an IC₅₀ value of 10.1 μM. α-Glucosidase-IN-31 significantly reduces the blood glucose level and has antidiabetic activity .

Cat. No.	Product Name

HY-L045

Oxygen Sensing Compound Library

2507 compounds

Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression.

Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival.

HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O₂ concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation.

MCE offers a unique collection of 2507 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0936

Coixol 1 Publications Verification 6-Methoxy-2-benzoxazolinone; 6-MBOA	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Gramineae Coix lacryma-jobi Linn. Plants Disease Research Fields	Others
Coixol (6-Methoxy-2-benzoxazolinone; 6-MBOA) is a potent and orally active anti-inflammatory agent. Coixol decreases the iNOS protein expression. Coixol inhibits the production of TNF-α, IL-6, and IL-1β. Coixol improves glucose tolerance and plasma insulin. Coixol decreases the blood glucose level .

HY-14860

1-Deoxynojirimycin 3 Publications Verification Duvoglustat	Alkaloids Piperidine Alkaloids Structural Classification Classification of Application Fields Source classification Metabolic Disease Plants Moraceae Disease Research Fields Morus alba Linn.	Glucosidase PI3K
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-14860A

1-Deoxynojirimycin hydrochloride 3 Publications Verification Duvoglustat hydrochloride	Commelinaceae Classification of Application Fields Source classification Metabolic Disease Commelina communis Plants Disease Research Fields Saccharides Monosaccharides	Glucosidase PI3K Bacterial Antibiotic
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-W010031

1-Methyluric acid	Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Other disease Source classification Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels.

HY-N12353

Stevisalioside A	Structural Classification Isodon hispidus (Bentham) Murata Polysaccharides Source classification Plants Compositae Saccharides	Phosphatase
Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC₅₀: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .

HY-N2421

Sequoyitol 1 Publications Verification 5-O-Methyl-myo-inositol	Natural Products Classification of Application Fields Leguminosae Glycine max (L.) merr Source classification Metabolic Disease Plants Disease Research Fields	Others
Sequoyitol (5-O-Methyl-myo-inositol) is isolated from plants. Sequoyitol (5-O-Methyl-myo-inositol) decreases blood glucose, improves glucose intolerance, and is used to treat diabetes .

HY-N3960

Glycyrin	Structural Classification Leguminosae Source classification Coumarins Phenylpropanoids Plants Glycyrrhiza uralensis Fisch.	PPAR Bacterial
Glycyrin is a PPAR-γ ligand of licorice. Glycyrin can decrease the blood glucose levels of genetically diabetic mice. Glycyrin also shows antibacterial activity .

HY-N4195

Resveratroloside 1 Publications Verification Resveratrol glycoside; trans-Resveratrol 4'-O-β-D-glucopyranoside	Cardiovascular Disease Structural Classification Stilbenes Classification of Application Fields Polygonaceae Source classification Reynoutria japonica Houtt. Phenols Polyphenols Plants Disease Research Fields	Glucosidase
Resveratroloside (Resveratrol glycoside) is a competitive inhibitior of α-glucosidase with an IC₅₀ of 22.9 μM. Resveratroloside has the ability to regulate PBG (postprandial blood glucose) levels. Resveratroloside exhibits cardioprotective effect .

HY-N11551

Salvifaricin	Artemisia frigida Willd. Structural Classification Terpenoids Labiatae Source classification Diterpenoids Plants	Others
Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .

HY-N3015

Bruceine E	Simaroubaceae Classification of Application Fields Terpenoids Source classification Metabolic Disease Diterpenoids Plants Disease Research Fields Brucea javanica (L.) Merr.	Others
Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ)-induced diabetic rats at lower dose .

HY-W050031

(S)-3-Hydroxybutanoic acid 1 Publications Verification (S)-β-Hydroxybutanoic acid; L-(+)-3-Hydroxybutyric acid; L-β-Hydroxybutyric acid	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
(S)-3-Hydroxybutanoic acid is a normal human metabolite, that has been found elevated in geriatric patients remitting from depression. In humans, 3-Hydroxybutyric acid is synthesized in the liver from acetyl-CoA, and can be used as an energy source by the brain when blood glucose is low.

HY-129297

CMPF	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .

HY-112624C

Dextran (MW 40000)	Structural Classification Human Gut Microbiota Metabolites Polysaccharides Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields Saccharides	Biochemical Assay Reagents Endogenous Metabolite
Dextran (MW 40000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds. Dextran has excellent solubility in water, making it useful as a viscosity modifier or stabilizer in foods, paints and adhesives. In the biomedical field, dextran is often used as a plasma expander because of its ability to increase blood volume when administered intravenously. It can also be modified to create dextran-based drug delivery systems, such as targeted nanoparticles.

HY-B2163

Astaxanthin 5 Publications Verification	Cardiovascular Disease Structural Classification Classification of Application Fields Anti-aging Source classification Whitening Agent Research on Agricultural Breeding Food Research Agricultural Research Microorganisms Sunscreen Terpenoids Pigments Diterpenoids Cosmetic Research Disease Research Fields	PPAR Reactive Oxygen Species STAT NF-κB Apoptosis
Astaxanthin, the red dietary carotenoid, is an orally effective and potent antioxidant. Astaxanthin inhibits NF-κB and down-regulates VEGF in blood glucose. Astaxanthin exerts anti-cancer cell proliferation, increases apoptosis, impairs migration and invasion by activating PPARγ and reducing the expression of STAT3. Astaxanthin also has neuroprotective and anti-inflammatory activity and can be used in studies of cancer, diabetic retinopathy, cardiovascular disease, and in the coloring of animal feed .

Cat. No.	Product Name	Chemical Structure

HY-B2099S

Buformin-d9 hydrochloride
Buformin-d₉ (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al)[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks